By Adriano Marchese
Fate Therapeutics has appointed Bob Valamehr to succeed Scott Wolchko as chief executive, effective a Jan. 1.
The clinical-stage biopharmaceutical company on Friday said that Valamehr has headed the development of its induced pluripotent stem cell platform, and led to 13 investigational new drug applications, covering the treatment of hematological malignancies, solid tumors and autoimmune disorders.
He is set to take over the day after Wolchko's effective retirement date of Dec. 31. Wolchko has led the San Diego-based company since 2015, and will continue to act as a strategic adviser to the company, Fate Therapeutics said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
November 29, 2024 13:38 ET (18:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Comments